ACE-106

ACE-106 (ACE-86225106) is an oral small-molecule inhibitor from Acerand Therapeutics. A highly selective PARP1 inhibitor taken by mouth. Its furthest stage is phase 2, for advanced solid tumours and BRCA-mutated ovarian, breast and prostate cancer (registry conditions). ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06380660 (sponsor Acerand Therapeutics (Shanghai)) active, not recruiting. Whether it works in people has not been established unless a trial below reports it.